<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954248</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-59616</org_study_id>
    <nct_id>NCT04954248</nct_id>
  </id_info>
  <brief_title>Pilot Study for Simultaneous PET-MR Imaging of Covid-19 Associated Neurological Complications Using a Brain Dedicated PET Insert</brief_title>
  <official_title>Pilot Study for Simultaneous PET-MR Imaging of Covid-19 Associated Neurological Complications Using a Brain Dedicated PET Insert</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this project is to study the feasibility of a prototype brain-dedicated&#xD;
      PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and&#xD;
      perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a&#xD;
      pilot study for establishing an imaging protocol for combined PET and MR derived functional&#xD;
      information as well as MRI acquired anatomical information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a non-randomized non-treatment study. The intention of this work is an&#xD;
      assessment of the PET insert technology, and not, for example, to perform a treatment&#xD;
      assessment or drug assessment. This work will actively recruit 10 individuals (5 Covid-19&#xD;
      negative and 5 Covid-19 previously positive in the last 90 days) to perform imaging of the&#xD;
      brain with an FDA-approved radiotracer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET/MR</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The key specific measurement is the resulting PET/MR image obtained from the single subject scan.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain Diseases</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Covid-19 Negative/Uninfected Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Covid-19 Positive/Infected Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Injected radiotracer with PET Insert</intervention_name>
    <description>Informed consent will be obtained before beginning any study procedures.&#xD;
Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.</description>
    <arm_group_label>Covid-19 Negative/Uninfected Population</arm_group_label>
    <arm_group_label>Covid-19 Positive/Infected Population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Whole body radiation dose in the last year of less than 5000 mrem determined via&#xD;
             subject verbal history reporting&#xD;
&#xD;
          2. Must be at least 21 years of age&#xD;
&#xD;
          3. Deemed healthy to endure duration of imaging study as confirmed via study PI&#xD;
&#xD;
          4. Proof of COVID-19 viral or antibody testing within the timeframe of &gt;20 days but &lt;90&#xD;
             days prior to scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of non-MRI compatible surgeries, implants, or activities&#xD;
&#xD;
          2. Pregnant or nursing&#xD;
&#xD;
          3. History of allergic reactions to PET radiotracers (via patient verbal report and /or&#xD;
             medical record review.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Marcellus</last_name>
    <phone>(650) 723-4547</phone>
    <email>dmarcel2@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Marcellus, BS</last_name>
      <phone>650-723-4547</phone>
      <email>dmarcel2@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Craig Levin</investigator_full_name>
    <investigator_title>Professor, Radiology/Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

